| Pharmaceutical Information |
| Drug Name |
Triheptanoin |
| Drug ID |
BADD_D02602 |
| Description |
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation.[L14612] In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly.[A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.[A214817]
Triheptanoin was granted FDA approval on 30 June 2020.[L14612] |
| Indications and Usage |
Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).[L14612] |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AX17 |
| DrugBank ID |
DB11677
|
| KEGG ID |
D11465
|
| MeSH ID |
C531010
|
| PubChem ID |
69286
|
| TTD Drug ID |
D00MLW
|
| NDC Product Code |
69794-050; 53194-000 |
| UNII |
2P6O7CFW5K
|
| Synonyms |
triheptanoin | glyceroltriheptanoate | glyceryl triheptanoate |
|
| Chemical Information |
| Molecular Formula |
C24H44O6 |
| CAS Registry Number |
620-67-7 |
| SMILES |
CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
